SV2A — Synaptic Vesicle Protein 2A

📖 Wiki Page

gene971 wordssynced 2026-04-02

SV2A Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SV2A — Synaptic Vesicle Protein 2A</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>SV2A</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Synaptic Vesicle Protein 2A</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>1p31.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>9902</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>158621</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000159166</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9H0Y5</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Alzheimer's Disease</td>
<td>SV2A expression reduced in AD brains; involved in synaptic loss</td>
</tr>
<tr>
<td class="label">Parkinson's Disease</td>
<td>Altered SV2A affects dopaminergic synapse function</td>
</tr>
<tr>
<td class="label">Epilepsy</td>
<td>SV2A is the therapeutic target for levetiracetum; mutations cause epilepsy</td>
</tr>
<tr>
<td class="label">Intellectual Disability</td>
<td>Haploinsufficiency affects synaptic vesicle function</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">SV2A</td>
<td>Levetiracetam (already approved)</td>
</tr>
<tr>
<td class="label">SV2A modulators</td>
<td>Novel anti-epileptic drugs</td>

...

SV2A Gene

Introduction

Sv2A — Synaptic Vesicle Protein 2A is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

SV2A (Synaptic Vesicle Protein 2A) is a gene encoding a major synaptic vesicle protein that functions as a regulator of neurotransmitter release and is the target of the anti-epileptic drug levetiracetam. [@bajjalieh1992]

Gene Information

Function

SV2A is an integral membrane protein localized to synaptic vesicles:

Neurotransmitter Release: Modulates vesicle fusion and neurotransmitter release kinetics
Levetiracetam Binding: Primary target for the antiepileptic drug levetiracetam (Keppra)
Vesicle Cycling: Involved in synaptic vesicle priming and fusion
Calcium Regulation: May play a role in calcium-dependent release
Synaptic Plasticity: Important for maintaining normal synaptic function and plasticity

Disease Associations

Expression

SV2A is expressed throughout the central nervous system:

Cerebral [cortex](/brain-regions/cortex) (pyramidal neurons)
[Hippocampus](/brain-regions/hippocampus) (CA1-CA3 regions)
Cerebellum (granule cells, Purkinje cells)
Basal ganglia
[Thalamus](/brain-regions/thalamus)
Brainstem
Spinal cord

Therapeutic Targeting

Key Publications

SV2A is the synaptic vesicle protein for levetiracetam - Nature (2004) - PMID: 14764983(https://pubmed.ncbi.nlm.nih.gov/14764983/)

SV2A structure and function - J Biol Chem (2008) - PMID: 18586678(https://pubmed.ncbi.nlm.nih.gov/18586678/)

SV2A in Alzheimer's disease - Brain (2012) - PMID: 22166481(https://pubmed.ncbi.nlm.nih.gov/22166481/)

SV2A and synaptic plasticity - Proc Natl Acad Sci (2015) - PMID: 25675510(https://pubmed.ncbi.nlm.nih.gov/25675510/)

Molecular Mechanisms

Structure and Topology

SV2A is a member of the major facilitator superfamily (MFS) of transporters:

[12 Transmembrane Domains*: Organized in a typical MFS fold](/genes/ran)
Cytoplasmic N- and C-termini: Long cytoplasmic loops for protein interactions
[Large Vesicular Lumen Loop*: External loop between TM1 and TM2](/genes/ar)
Conserved Motifs: MFS signature sequences in TM 2, 5, 8, and 11

Levetiracetam Binding

The SV2A protein is the direct target of levetiracetam:

[Binding Site*: Located within transmembrane domains](/genes/ran)
[Conformational Change*: Drug binding alters SV2A function](/genes/nct)
[Synaptic Vesicle Release*: Modulates release probability](/genes/rel)
[Affinities*: SV2A > SV2B > SV2C for levetiracetam binding](/genes/sv2c)

Modulation of Neurotransmitter Release

SV2A regulates synaptic transmission through multiple mechanisms:

Vesicle Priming: Facilitates preparation of vesicles for release
Fusion Machinery: Interacts with SNARE complex proteins
Calcium Sensing: May modulate calcium entry through voltage-gated channels
Release Probability: Reduces asynchronous release; normalizes synchronous release

SV2 Isoforms and Function

Three SV2 isoforms exist with distinct distributions:

SV2A: Ubiquitous in all synaptic terminals; essential for viability
SV2B: Predominantly in retina and some brain regions
SV2C: Found in basal ganglia and olfactory bulb

Role in Neurodegeneration

Alzheimer's Disease

SV2A dysfunction contributes to synaptic failure in AD:

Expression Reduction: 30-50% reduction in AD hippocampus
Synaptic Loss: Correlates with cognitive decline
[Aβ](/proteins/amyloid-beta) Effects: [Aβ](/proteins/amyloid-beta) oligomers reduce SV2A expression
Therapeutic Potential: SV2A modulators may protect synapses

Parkinson's Disease

Dopaminergic terminals show specific vulnerabilities:

Vesicle Cycling: High-frequency release demands efficient SV2A function
[Alpha-Synuclein](/mechanisms/alpha-synuclein) Interaction: α-syn may affect SV2A trafficking
Levetiracetam Effects: Being investigated for PD cognitive dysfunction

Epilepsy

SV2A is central to epilepsy treatment:

Levetiracetam: First-line anti-epileptic drug targeting SV2A
Mechanism: Reduces seizure frequency by modulating SV2A function
Drug Resistance: Some patients show reduced SV2A expression
Novel Therapies: Next-generation SV2A modulators in development

Therapeutic Implications

Anti-Epileptic Drugs

Neurodegeneration

Synaptic Protection: SV2A modulators may protect against synaptic loss
Combination Therapies: SV2A targeting with other mechanisms
Biomarker Potential: SV2A PET ligands for synaptic density

Animal Models

Knockout Studies

SV2A KO Mice: Viable but reduced seizure threshold
Conditional KO: Region-specific deletion reveals circuit roles
SV2B/SV2C Double KO: Compensatory mechanisms between isoforms

Disease Models

Epilepsy Models: SV2A expression changes during seizures
AD Models: SV2A reduction in [APP](/entities/app-protein) transgenic mice
Therapeutic Testing: Levetiracetam efficacy in mouse models

Research Directions

Structural Studies: Cryo-EM of SV2A-ligand complexes
PET Ligands: [^11C]UCB-J for synaptic density imaging
Gene Therapy: AAV-SV2A for epilepsy treatment
Biomarkers: SV2A as marker of synaptic health

Clinical Significance

SV2A mutations and variations:

Epilepsy: Rare mutations cause early-onset epilepsy
Psychiatric Disorders: Association with schizophrenia and depression
Drug Response: SV2A variants affect levetiracetam response

Background

The study of Sv2A — Synaptic Vesicle Protein 2A has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

External Links

[NCBI Gene: SV2A](/- [UniProt: SV2A](https://www.uniprot.org/uniprot/Q9H0Y5)
[GeneCards: SV2A](https://www.genecards.org/cgi-bin/card- [OMIM: SV2A](https://www.omim.org/entry/158621)

Pathway Diagram

The following diagram shows the key molecular relationships involving SV2A — Synaptic Vesicle Protein 2A discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

SV2A — Synaptic Vesicle Protein 2A

SV2A Gene

SV2A Gene

Introduction

Overview

Gene Information

Function

Disease Associations

Expression

Therapeutic Targeting

Key Publications

See Also

Molecular Mechanisms

Structure and Topology

Levetiracetam Binding

Modulation of Neurotransmitter Release

SV2 Isoforms and Function

Role in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Epilepsy

Therapeutic Implications

Anti-Epileptic Drugs

Neurodegeneration

Animal Models

Knockout Studies

Disease Models

Research Directions

Clinical Significance

Background

References

External Links

Pathway Diagram